HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trinity submits CLIA application for TRIstat HbA1c test

This article was originally published in Clinica

Executive Summary

Trinity Biotech has applied to the US FDA for a CLIA waiver for its TRIstat point-of-care HbA1c blood test. The test measures glycated haemoglobin, an indicator of diabetic patients' average blood sugar control over the past two to three months. It provides results "in minutes" and does not require refrigeration, unlike other available HbA1c tests, Bray, Ireland-based Trinity says. TRIstat received FDA 510(k) clearance in December 2007, but CLIA-waived status would mean it could be used by non-laboratory trained physicians in CLIA-certified labs.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT043869

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel